Pfizer Inc. has described nucleoprotein N (respiratory syncytial virus [RSV]) inhibitors reported to be useful for the treatment of RSV infection.

University of Maryland has divulged pyrazinamide (PZA)-mimicking prodrugs reported to be useful for the treatment of tuberculosis.

Institut National Supérieur des Sciences Agronomiques de l’Alimentation et de l'Environnement has identified compounds reported to be useful for the treatment of cryptosporidiosis. 

Shemyakin Institute of Bioorganic Chemistry has synthesized perylenylethynylphenol derivatives acting as photosensitizers for photodynamic therapy reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).

Sunshine Lake Pharma Co. Ltd. has disclosed Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer, psoriasis and rheumatoid arthritis.

Bristol Myers Squibb Co. has identified new GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.

Muscarinic M4 receptor positive allosteric modulators are detailed in an Acadia Pharmaceuticals Inc. patent. They are reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia, Huntington’s disease, Parkinson’s disease, psychosis and drug abuse and dependence.

Genep Inc. has prepared and tested Imidazole compounds acting as sodium channel protein type 8 subunit α (SCN8A; Nav1.6) blockers reported to be useful for the treatment of epilepsy.

Blossomhill Therapeutics Inc. has synthesized new indazole-based macrocyclic compounds acting as ALK tyrosine kinase receptor inhibitors potentially useful for the treatment of cancer.

Atai Therapeutics Inc. has patented new 5-HT2A receptor agonists reported to be useful for the treatment of substance abuse and dependence, treatment-resistant depression, major depression, anxiety, eating, obsessive-compulsive and stress disorder.